N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L.
Miner SE, et al. Among authors: daly p.
Am Heart J. 2004 Oct;148(4):690-5. doi: 10.1016/j.ahj.2004.05.015.
Am Heart J. 2004.
PMID: 15459602
Clinical Trial.